Welcome to our dedicated page for Atricure news (Ticker: ATRC), a resource for investors and traders seeking the latest updates and insights on Atricure stock.
AtriCure, Inc. (ATRC) delivers pioneering medical technologies for cardiac arrhythmia treatment and minimally invasive surgical solutions. This dedicated news hub provides investors and healthcare professionals with essential updates on corporate developments, clinical advancements, and regulatory milestones.
Access timely information on FDA-cleared devices, atrial fibrillation treatment innovations, and strategic partnerships. Our curated collection includes earnings reports, product launch announcements, and peer-reviewed study results directly impacting cardiac care practices.
Key updates cover ablation system enhancements, left atrial appendage management solutions, and operational expansions. Bookmark this page for structured access to AtriCure's latest advancements in electrophysiology and cardiothoracic surgical technologies.
AtriCure reported strong Q1 2025 financial results with worldwide revenue reaching $123.6 million, marking a 13.6% year-over-year increase. The company showed significant improvement in its net loss position, reducing it to $6.7 million from $13.3 million in the previous year.
Key highlights include:
- U.S. revenue grew 12.1% to $101.1 million
- International revenue increased 20.8% to $22.5 million
- Gross margin improved to 74.9%
- Adjusted EBITDA reached $8.8 million, up by $6.0 million
Growth was driven by strong sales across product lines, including the EnCompass clamp, cryoSPHERE MAX probes, and AtriClip Flex·Mini device. Management updated 2025 guidance, projecting full-year revenue between $517-527 million and adjusted EBITDA of $44-46 million.
AtriCure (Nasdaq: ATRC) has announced the first use of its newly FDA-cleared AtriClip PRO-Mini® LAA Exclusion System, designed for minimally invasive concomitant procedures. The device represents a significant advancement in left atrial appendage (LAA) management technology.
The innovative device features a 60% smaller profile compared to the next lowest profile AtriClip device, providing surgeons with enhanced visualization and precise LAA exclusion capabilities. Key benefits include uniform pressure application for reliable closure, omnidirectional head articulation, and streamlined applier removal.
Dr. Ahmed Romeya from Midwest Heart and Vascular Specialists highlighted the device's smaller profile and parallel closure capabilities, noting increased surgeon confidence during procedures. This latest addition builds upon AtriCure's 20+ year legacy in surgical appendage management and their position as the provider of the most widely implanted surgical LAA device globally.
AtriCure (Nasdaq: ATRC), a company specializing in surgical treatments for atrial fibrillation, left atrial appendage management, and post-operative pain management, has scheduled the release of its first quarter 2025 financial results for Tuesday, April 29, 2025.
The company will host an audio webcast at 4:30 p.m. Eastern Time on the same day to discuss the quarterly results. Interested participants are advised to register online more than 15 minutes before the call begins. Both live and replay versions of the webcast will be accessible through the company's investor relations website.
AtriCure (Nasdaq: ATRC), a pioneer in surgical treatments for atrial fibrillation, left atrial appendage management, and post-operative pain management, has announced its upcoming Analyst & Investor Day scheduled for March 26, 2025.
The event will take place at the company's headquarters in Mason, Ohio, running from 1:00 PM to 4:00 PM ET. During the presentation, AtriCure will showcase its product portfolio and innovative pipeline for market expansion, featuring insights from key opinion leaders and sharing long-term financial objectives focused on growth and increased profitability.
Interested parties can access both live and archived webcasts of the presentation and Q&A sessions through the Investors section of AtriCure's website at https://ir.atricure.com.
AtriCure (ATRC) reported strong financial results for Q4 and full-year 2024. Q4 revenue reached $124.3 million, up 16.6% year-over-year, while full-year revenue grew 16.5% to $465.3 million. U.S. revenue increased 14.4% to $101.6 million in Q4, driven by sales of cryoSPHERE probes, AtriClip Flex-V devices, and EnCompass clamp. International revenue rose 27.7% to $22.7 million.
The company reported a Q4 net loss of $0.33 per share, compared to $0.21 in Q4 2023. Adjusted EBITDA was positive at $12.7 million for Q4 2024. For 2025, AtriCure projects revenue between $517-527 million and positive adjusted EBITDA of $42-44 million.
Notable developments include the launch of new products: cryoSPHERE+, cryoSPHERE MAX, AtriClip FLEX-Mini in the U.S., and EnCompass clamp in Europe.
AtriCure (Nasdaq: ATRC), a company specializing in surgical treatments for atrial fibrillation, left atrial appendage management, and post-operative pain management, has announced it will release its fourth quarter and full year 2024 financial results on Wednesday, February 12, 2025.
The company will host an audio webcast at 4:30 p.m. Eastern Time on the same day to discuss the financial results. Interested participants are advised to register online more than 15 minutes before the call begins. Both live and replay versions of the webcast will be accessible through AtriCure's investor relations website.
AtriCure has announced its preliminary financial results for Q4 and full year 2024, alongside its 2025 financial guidance.
Preliminary, unaudited revenue for Q4 2024 is expected to be $124.3 million, a growth of approximately 17% over Q4 2023. U.S. revenue is projected at $101.6 million (14% growth), and international revenue at $22.7 million (28% growth). This growth is driven by strong performance in cryoSPHERE® devices, AtriClip® devices, and the EnCompass® clamp.
For the full year 2024, revenue is expected to be $465.3 million, up by 17% from 2023. Adjusted EBITDA is anticipated to be around $26 million to $29 million, with an adjusted loss per share of $0.74 to $0.80.
Looking ahead, AtriCure projects 2025 revenue between $517 million and $527 million, with positive adjusted EBITDA of $40 million to $44 million and modest cash flow generation. The company will host an Analyst & Investor Day on March 26, 2025, to discuss its product portfolio, innovative pipeline, and long-term financial goals.
AtriCure (Nasdaq: ATRC), a leader in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference.
The event will take place on Wednesday, January 15, 2025, at 3:00 pm Pacific Standard Time. AtriCure’s management will present at this conference. Interested individuals can access a live audio webcast of the presentation by visiting the “Investors” section of the company’s website at https://ir.atricure.com.
AtriCure (Nasdaq: ATRC), a company specializing in surgical treatments for atrial fibrillation, left atrial appendage management, and post-operative pain management, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The company's management will engage in a fireside discussion on Wednesday, December 4, 2024, at 9:00 am EST. The presentation will be accessible via live audio webcast through the Investors section of AtriCure's website.
AtriCure (Nasdaq: ATRC), a company specializing in surgical treatments for atrial fibrillation, left atrial appendage management, and post-operative pain management, has announced its participation in the Stifel 2024 Healthcare Conference. The company's management will engage in a fireside chat on Monday, November 18, 2024, at 9:10 am EST. A live audio webcast of the presentation will be accessible through the 'Investors' section of AtriCure's website.
FAQ
What is the current stock price of Atricure (ATRC)?
What is the market cap of Atricure (ATRC)?
